Financial Performance - Revenue for Q3 2024 was CNY 964,416,198.78, a decrease of 24.23% year-over-year, and a decline of 38.63% for the year-to-date period[2] - Net profit attributable to shareholders for Q3 2024 was CNY 65,036,596.96, down 49.32% year-over-year, with a year-to-date decline of 62.98%[2] - Basic earnings per share for Q3 2024 was CNY 0.11, a decrease of 56.00% compared to the same period last year[2] - The company reported a decrease of 8.45% in after-market business revenue in Q3 2024 compared to Q2 2024[10] - The net profit for Q3 2024 was CNY 177,825,699.50, a decrease of 63.2% compared to CNY 483,568,613.16 in the same period last year[16] - The total profit for Q3 2024 was CNY 206,442,377.66, down 63.5% from CNY 566,618,992.81 year-on-year[16] - The basic and diluted earnings per share for Q3 2024 were both CNY 0.3, compared to CNY 0.95 in Q3 2023, reflecting a decline of 68.4%[17] - The operating profit for Q3 2024 was CNY 205,063,551.98, down 63.5% from CNY 561,519,896.41 in Q3 2023[16] - The company reported a total comprehensive income of CNY 179,044,563.81 for Q3 2024, a decrease of 63.0% from CNY 484,676,320.30 in the previous year[17] Assets and Liabilities - Total assets at the end of Q3 2024 were CNY 5,420,215,803.69, a decrease of 2.90% from the end of the previous year[2] - Cash and cash equivalents at the end of the period are CNY 2,073,695,114.52, down from CNY 2,876,944,465.70, representing a decrease of about 28.0%[12] - Total assets decreased to CNY 5,420,215,803.69 from CNY 5,581,938,346.00, a reduction of approximately 2.9%[14] - Total liabilities decreased to CNY 838,559,627.22 from CNY 919,022,185.07, reflecting a decline of about 8.8%[14] - The company's equity attributable to shareholders decreased to CNY 4,583,838,513.69 from CNY 4,662,844,409.26, a decrease of approximately 1.7%[14] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 266,175,140.58, down 51.65% year-over-year[6] - Cash inflow from operating activities for Q3 2024 was CNY 2,460,101,646.70, down 41.5% from CNY 4,198,667,910.46 in the previous year[18] - Cash outflow from investing activities totaled CNY 1,367,093,960.26 in Q3 2024, significantly higher than CNY 130,141,633.96 in Q3 2023[19] - The net cash flow from investing activities was negative CNY 739,519,360.27, compared to negative CNY 129,291,633.96 in the same quarter last year[19] - The cash and cash equivalents at the end of Q3 2024 were CNY 2,072,244,267.76, down from CNY 3,704,308,295.88 at the end of Q3 2023[19] Revenue Segments - The company achieved operating revenue of CNY 2,354.15 million for the first nine months of 2024, representing a 61.37% increase compared to the same period last year[10] - In Q3 2024, the company reported operating revenue of CNY 964.42 million, a 25.19% increase from Q2 2024, with container revenue growing by 29.06%[10] - The medical equipment components segment generated CNY 171.29 million in revenue, exceeding last year's performance by 104.18%[10] Investment and Funding - The company plans to use CNY 600 million of temporarily idle raised funds for cash management, investing in high-security, liquid products with a maturity of no more than 12 months[11] - The board approved the use of CNY 300 million of excess raised funds to permanently supplement working capital for daily operations[11] - The company has adjusted the internal investment structure and construction period for certain fundraising projects while maintaining the original investment purposes[10] Other Financial Metrics - The company experienced a 175.25% increase in credit impairment losses, mainly due to changes in accounts receivable[5] - Investment income increased by 63.11% year-over-year, attributed to gains from foreign exchange contracts and equity transfers[5] - Non-operating income decreased by 78.43% year-over-year, primarily due to fewer compensation receipts compared to the previous year[5] - Research and development expenses decreased to CNY 89,713,934.69 from CNY 123,356,141.37, a decline of approximately 27.2%[15] - The company reported a net investment loss of CNY 19,042,225.97, an improvement compared to a loss of CNY 51,621,781.76 in the previous period[15] - The company’s financial expenses showed a significant improvement, with a net financial income of CNY 30,731,057.96 compared to a loss in the previous period[15] - The company’s inventory decreased to CNY 922,746,772.93 from CNY 970,715,930.82, a decline of approximately 4.9%[12]
中集环科(301559) - 2024 Q3 - 季度财报